Trial Profile
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Adminstered ISIS 443139 in Patients With Early Manifest Huntington's Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tominersen (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; First in man
- Sponsors Ionis Pharmaceuticals
- 01 May 2020 Results presented at the 72nd Annual Meeting of the American Academy of Neurology
- 07 Aug 2019 According to an Ionis Pharmaceuticals media release, Roche plans to present data from the open label extension portion of the study
- 09 May 2019 According to an Ionis Pharmaceuticals media release, data from the study were presented at the 2019 AAN Annual Meeting.